Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655484 | 0.98 | USP2 (0.71) | ALDH1A1USP2HSD17B10MEN1KMT2A | |
| SCHEMBL13982817 | 0.96 | ALDH1A1 (0.65) | ALDH1A1USP2HSD17B10PKMMEN1 | |
| SCHEMBL14094061 | 0.84 | L3MBTL1 (0.68) | ALDH1A1HSD17B10MEN1KMT2APOLB | |
| SCHEMBL16809210 | 0.84 | MAPT (0.63) | ALDH1A1USP2PKMMAPT | |
| SCHEMBL14057770 | 0.82 | KMT2A (0.51) | ALDH1A1MEN1KMT2ATDP1HTT | |
| SCHEMBL12455096 | 0.81 | USP2 (0.68) | ALDH1A1USP2HSD17B10PKMMEN1 | |
| SCHEMBL13982806 | 0.81 | USP2 (0.67) | ALDH1A1USP2HSD17B10MEN1KMT2A | |
| SCHEMBL14538786 | 0.80 | AKR1C3 (0.58) | ALDH1A1USP2MEN1KMT2ATDP1 | |
| SCHEMBL6945990 | 0.80 | USP2 (0.71) | ALDH1A1USP2HSD17B10MEN1KMT2A | |
| SCHEMBL12793711 | 0.80 | USP2 (0.71) | ALDH1A1USP2HSD17B10PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975399-B2 | Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF | VAX-CONSULTING (FR) | 2015-03-10 | — | — | US | disclosed |
| US-8975399-B2 | Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF | VAX-CONSULTING (FR) | 2015-03-10 | — | — | US | disclosed |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | VAX-CONSULTING (FR) | 2013-05-16 | — | — | US | disclosed |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | VAX-CONSULTING (FR) | 2013-05-16 | — | — | US | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR88 | ALDH1A1 2125/4885USP2 3877/4885HSD17B10 4462/4885 |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | TNF, TNFRSF1A, TRAF6 | ALDH1A1 205/4885USP2 1074/4885HSD17B10 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.